Diclofenac - Iroko Pharmaceuticals

Drug Profile

Diclofenac - Iroko Pharmaceuticals

Alternative Names: Diclofenac nano-formulation - Iroko Pharmaceuticals; Diclofenac Test; IP 880; lower dose submicron diclofenac - Iroko; Zorvolex

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator iCeutica
  • Developer Algorithm; Iroko Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute pain; Musculoskeletal pain; Postoperative pain
  • No development reported Dental pain

Most Recent Events

  • 07 Dec 2016 Iroko files a Paragraph IV law suit against Lupin alleging the infringement of Iroko's patents protecting the Zorvolex® products
  • 01 Apr 2016 Iroko Pharmaceuticals completes a phase II trial for Postoperative pain (In children, In adolescents) in USA (NCT02424578)
  • 02 Oct 2015 No recent reports of development identified - Phase-II for Dental pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top